BIRC5-specific T lymphocytes which recognize colorectal cancer cells and BIRC5-specific class I HLA-restricted T lymphocytes were activated and released interleukin 2 in response to HLA/ BIRC5-peptide complexes expressed by tumor cells. This evidence concerns the gene IL2 and neoplasm.